CellSeed

CellSeed Debt Growth

The Year-over-Year Debt Growth of CellSeed (7776.T) as of Nov 1, 2026 is -7.54 %. In the previous year, Year-over-Year Debt Growth was -4.96 % — a change of 51.99% (lower).

Debt Growth

-7.54 %

YoY

51.99%

Last updated:

Year-over-Year Debt Growth of CellSeed is 2025 -7.54 % . Year-over-Year Debt Growth of CellSeed was 2024 -4.96 % . It decreases by 51.99% lower compared to the previous year.

The CellSeed Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2021
0.00 JPY
Jan 1, 2022
-0.78 JPY
Jan 1, 2023
-4.72 JPY
Jan 1, 2024
-4.96 JPY
Jan 1, 2025
-7.54 JPY
The CellSeed Debt Growth history
YEARDebt GrowthYoY
-7.54 %+51.99%
-4.96 %+4.96%
-4.72 %+504.72%
-0.78 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Year-over-Year Debt Growth of CellSeed is -7.54 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth CellSeed since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's CellSeed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — CellSeed

All Key Metrics — CellSeed